Maxim Group analyst Anthony Vendetti upgrades Joint (NASDAQ:JYNT) from Hold to Buy and announces $36 price target.
Zentalis Announces Preclinical Data Supporting Cyclin E1 As A Predictive Marker For Azenosertib Treatment At AACR Annual Meeting 2023
Data suggest Cyclin E1 plays a critical role in high proportion of multiple tumor types including platinum-resistant ovarian cancer
Company anticipates sharing clinical data from ovarian chemotherapy combination
